Kornimate/medical-research-clean huggingface dataset:
evaluation of the communities of healing mentorship/support group program: assessment of preliminary efficacy

Conditions: Eating Disorder; Anorexia Nervosa; Bulimia Nervosa; Binge-Eating Disorder

Summary: the goal of the study is to evaluate two 6-month adjunct interventions (peer mentorship and social support mentorship) for individuals with eating disorders. individuals will be randomized to peer-mentorship, social support mentorship, or a wait-list and eating disorder symptoms will be evaluated at baseline and post-treatment.

eating disorders are serious mental illnesses associated with significant morbidity and high relapse rates. patients are at especially high risk of relapse after leaving structured treatment (e.g., hospitalization). adjunct interventions targeting patients' motivation and participation in treatment at these times may help patients recover from eating disorders. project heal is a non-profit organization whose mission is to reduce suffering caused by eating disorders, and they have recently developed two adjunct, mentorship-based interventions for patients in recovery. in the peer mentorship condition, individuals meet weekly with a peer mentor who has previously recovered from an eating disorder in order to discuss symptoms and coping strategies. in the social support mentorship condition, individuals meet weekly with a social support mentor who has not personally struggled with an eating disorder in order to engage in activities unrelated to the eating disorder. the aim of the current study is to evaluate the feasibility and efficacy of this intervention. the design of the study is a three-arm randomized controlled trial comparing peer mentorship, social-support mentorship, and wait-list control conditions. participants in the study will be randomized to one of the three conditions for six months. wait-list participants will subsequently receive either type of mentorship. participants will complete assessments of their eating disorder symptoms at baseline, monthly throughout the course of the study, and one year after beginning the study. outcomes will be compared between groups.

Eligibility criteria:
inclusion criteria: * current or past 6 months an, bn, or bed * recent (within 6 months) discharge from structured treatment * involved in outpatient treatment at an appropriate level of care * medical stability * access to smart phone or computer to complete study assessments exclusion criteria: * evidence of needing specialized treatment for another medical or mental health condition
de-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you

Conditions: Breast Cancer

Summary: this is a live biobank study for breast cancer (bc) patients where samples will be collected at inflection points in the course of the disease.

to test this hypothesis the investigators will focus on studying bc patients using an innovative approach, the dignity study (de-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you) designed to building a live tissue biobank of patient derived tumor organoids (pdos) derived from tumor at surgery, preceded or not by neoadjuvant therapy (nat), and at recurrence/metastasis. bc patients enrolled in this study are consented to enable investigators to generate a biobank of tumor tissue (obtained from surgically removed excess that would otherwise be disposed off ) and matched blood cells ( obtained from an already existing line or a venipuncture ordered per standard of care testing) at key timepoints in their treatment course.

Eligibility criteria:
inclusion criteria: * all patients will historically proven bc are eligible to be on the study exclusion criteria: * carriers of other cancers other than breast.
metacognition assessment in patient with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study will assessed the level of consciousness of ms patients suffering of cognitive and motor disorders. understanding the awareness of the disease is crucial to allow better management of these patients. it has been shown, for other neurological pathologies, that a lack of awareness of deficits leads to inefficient rehabilitation and a disorder of understanding the impact of deficits in daily activities. metacognition could be altered with age, so we will include participants between 18 and 60 years old.

subject who have to do neurological assessement by the multiple sclerosis functional composite (msfc) will be enrolled. the patient will estimate the time to undergo the test. this time will be compared to the time really make by the patient to realise test.

Eligibility criteria:
inclusion criteria: * diagnosis of multiple sclerosis * voluntary for participate to study exclusion criteria: * neurological disease other than multiple sclerosis * psychiatric disease, other than depressiveness * illicit substance abuse * persons referred to in articles l1121-5 to 8 of the french public health code

Keywords: multiple sclerosis multiple sclerosis functional composite (msfc) metacognition
transcranial direct current stimulation for migraine attack

Conditions: Acute Migraine

Summary: this study is conducted to investigate the therapeutic efficacy and safety of transcranial direct current stimulation (tdcs) over the primary motor cortex of patients with acute migraine attack.


Eligibility criteria:
inclusion criteria: * aged 17-70 years * migraine * with or without aura * the first attack of migraine was earlier than 50 years of age * one to 8 moderate to severe migraine attacks per month in the 2 months preceding the screening * willing and able to give written informed consent * able to read, comprehend and complete the diary form exclusion criteria: * not able to distinguish between migraine and non-migraine headache * combined headache, including the tension type headache and medication overuse headache * pregnant, actively trying to become pregnant or breast-feeding women * uncontrolled and significant medical illness * vertebrobasilar or hemiplegic migraine according to the international headache society diagnostic criteria * having intracranial metal implants or a cardiac pacemaker * a history of epilepsy or other organic brain disorders * a history of psychological diseases * having changed medications for migraine within 1 month before giving us informed consent * drug abuser or alcoholics
assessing insulin sensitivity and diabetes risk in childhood cancer survivors treated with abdominal irradiation

Conditions: Childhood Cancer Survivors Treated With Abdominal Radiation

Summary: the purpose of this study is to better understand the risk factors and causes of diabetes in people who received radiation to the abdomen as children. the investigators hope this information will allow them to improve how they screen people at risk for diabetes and how they treat patients in the future.


Eligibility criteria:
inclusion criteria: * diagnosis of childhood cancer between 0-21 years of age * prior treatment with abdominal radiation at mskcc * two or more years from completion of therapy * records of cancer diagnosis and treatment (including radiation records) available exclusion criteria: * known diagnosis of diabetes * previous treatment with any radiation impacting the brain (cranial radiation, craniospinal radiation, total body irradiation) * neurocognitive deficits that impair ability to give informed consent or assent * patients predicted to have difficult intravenous access, who will likely require multiple venipuncture attempts

Keywords: diabetes risk 14-202
prevalence of severe bleeding in covid-19 patients treated with higher than recommended thromboprophylaxis doses

Conditions: COVID-19

Summary: the main objectives are: * to establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. * to identify variables associated to higher risk of bleeding.


Eligibility criteria:
inclusion criteria: * patients infected with covid-19 treated with higher than recommended thromboprophylaxis doses. * admission to hospital. exclusion criteria: * patients treated with ecmo (extracorporeal membrane oxygenation).
zostavax™ (zoster vaccine live) long-term effectiveness study (v211-024)

Conditions: Herpes Zoster; Shingles

Summary: this study will describe the impact of vaccination with zostavax™ on the epidemiology of herpes zoster (hz) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.


Eligibility criteria:
inclusion criteria: * participants with continuous kaiser permanente northern california (kpnc) membership since becoming age-eligible for zostavax™ and with 12 months of continuous enrollment in kpnc before their study start date exclusion criteria:

Keywords: varicella-zoster vaccine herpes zoster shingles varicella-zoster virus postherpetic neuralgia herpesviridae infections dna virus infections virus diseases
efficacy and safety of transcranial direct current stimulation (tdcs) in progressive supranuclear palsy (psp) (stim-psp)

Conditions: Progressive Supranuclear Palsy; Motor and Cognitive Symptoms

Summary: this is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tdcs) on cognitive and motor symptoms in progressive supranuclear palsy (psp) over the left dorsolateral prefrontal cortex (dlpfc).

progressive supranuclear palsy (psp) is a rapidly progressive neurodegenerative disease characterized by deposition of tau and motor, cognitive and behavioral symptoms. since no effective treatment is available, non-invasive brain stimulation techniques, such as tdcs, could be a valid complementary therapeutic approach. the tdcs modulates the spontaneous activity of the neural network by applying a direct current flow on the cortical brain areas (anodic or cathodic stimulation). despite its efficacy in psychiatric disorders, the therapeutic use of tdcs in neurodegenerative diseases requires more systematic studies. the aim of this study is to verify the safety and efficacy of tdcs in psp on motor, cognitive and behavioral symptoms.

Eligibility criteria:
inclusion criteria: * diagnosis of psp according with movement disorder society (mds) criteria (hoglinger et al., 2017); * age \> 40 and \< 89 years; * presence of a caregiver supportive the patient for all study procedure; * ability to walk for at least 5 steps either independently or with a minimum support (another patients holding patient's arm or with a walker) exclusion criteria: * presence of electrical stimulators (for example, pacemaker, deep brain stimulation, dbs) * difficult in understanding italian language * presence of severe sensory deficits (for example, visual or hearing impairments) * education level \<5 years * history of drug abuse * history of severe psychiatric disorders * history of transient ischemic attacks * cortical or sub-cortical vascular lesions * seizures or severe heart problems and previous neurosurgical operations * absence of subjective cognitive deficits * mmse (mini-mental state examination) score \<20 * left-handedness

Keywords: progressive supranuclear palsy (psp) transcranial direct current stimulation (tdcs)
pharmacokinetics of bpdo-1603 or bpdo-16031 and bpdo-16033 administration in healthy adults

Conditions: Healthy

Summary: pharmacokinetics and safety of bpdo-1603 or bpdo-16031 and bpdo-16033 administration in healthy adults. randomized, open-label, single-dose, cross-over, phase 1 study


Eligibility criteria:
inclusion criteria: 1. healthy adults aged 19 or older and 55 or less at the time of screening tests 2. men weigh 55 kg or more and women weigh 50 kg or more 3. those with a body mass index of 18.5 kg/m2 or more and less than 27.0 kg/m2 exclusion criteria: 1. clinically significant active chronic diseases, hepatometer (severe liver disorder, etc.), kidney (severe kidney disorder, etc.), and nervous system (hepatorespiratory tract patients). parkinson's disease, immune system, respiratory system (asthenia, obstructive pulmonary disease, etc.), urinary system, digestive system (digestive ulcer, etc.), endocrine system, blood/tumor, cardiovascular system (cardiac infarction, heart failure, uncontrolled hypertension, atrioventricular junction disorder, etc.), or have a history. 2. a person who has a serious urinary tract infection due to renal tubular acidosis, etc. or has a history of history 3. those with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption

Keywords: alzheimer's disease, dementia
effectiveness of non-surgical interventions for the trigger finger: a randomized clinical trial

Conditions: Trigger Finger

Summary: the aim of this study is to assess the effectiveness of therapeutic modalities (paraffin, ultrasound and orthotics) versus corticosteroid injection for trigger finger.

there are several forms of nonsurgical treatment for trigger finger, the most used are: * oral nonsteroidal and steroidal antiinflammatory's drugs use to resolve the inflammatory process * corticosteroids local injection: that proposes to control the inflammation, these injections have shown good effectiveness for trigger finger treatment. * orthotic: with the aim of to immobilize the affected joint until the resolution of the inflammatory process. * electrotherapeutic modalities: * paraffin that increases cellular metabolism and promotes peripheral vasodilatation, favoring the transduction tissue fluid, lymph flow, hyperemia and consequent absorption of exsudato. * laser -lower level laser therapy (lllt): the absorption of light through the skin's photoreceptors stimulates mitochondrial chain reactions, promoting adenosine triphosphate (atp) synthesis, acting on gene expression, which raises the level of growth factors and tissue repair although the non-surgical treatment is often used there is no evidence in the literature of which is the most effective conservative treatment for trigger finger. thus, it is necessary use appropriate methodology to define the benefits and harms of each treatment modality and assess the effectiveness of these nonsurgical treatments, and may define which one has a higher resolution and lower rates of trigger finger recurrences in short, medium and long term.

Eligibility criteria:
inclusion criteria: * 2-3 grade of trigger finger (quinnell´s classification) * signing the terms of consent. exclusion criteria: * presence of finger trigger in children * presence of traumatic finger trigger * secondary causes (patients with tumor of the tendon sheath, synovitis tuberculosis, etc ...)

Keywords: trigger finger therapeutic modalities corticosteroid injection non-surgical treatment physical therapy
study of antenatal care intervention directed to pregnant women with obesity

Conditions: Obesity Complicating Childbirth

Summary: the purpose of this study is to determine whether a behavioural intervention focusing on diet and physical activity is cost-effective in decreasing weight gain during pregnancy among pregnant women with body mass index above 30, and has effect on the weight of offspring at birth and at 2.5 years of age

obesity in relation to pregnancy is becoming an increasing public health issue and 48% of women assigned to antenatal care in sweden have overweight (bmi≥25) or obesity (bmi≥30). obesity is associated with adverse perinatal outcomes, the risks increase with increasing bmi and excessive gestational weight gain (gwg) further increases the risks of adverse pregnancy outcomes. lifestyle intervention can help pregnant women with obesity to limit their gwg. this study evaluated whether a low-budget antenatal lifestyle intervention programme, with emphasis on nutrition and physical activity, influenced gwg and maternal and perinatal outcomes for pregnant women with obesity. the study also evaluated which specific components of the intervention that had effect.

Eligibility criteria:
inclusion criteria: * pregnant * bmi\>30 exclusion criteria: * first antenatal care visit after week 20 of the pregnancy * abortion * miscarriage

Keywords: obesity pregnancy lifestyle gestational weight gain weight of offspring antenatal care health behavior physical activity diet programme evaluation costs and costs analysis
improve hf: registry to improve the use of evidence-based heart failure therapies in the outpatient setting

Conditions: Heart Failure, Congestive; Myocardial Infarction; Ventricular Dysfunction, Left

Summary: the purpose of this study is to characterize current management of patients with either heart failure or prior myocardial infarction and left ventricular dysfunction and to assess the effect of education, specific clinical guidelines, reminder systems, comprehensive disease state management tools, benchmarked quality reports, and academic detailing on the use of evidence-based heart failure therapies in cardiology practices. this study is a quality improvement initiative that is being conducted through review of patient records.

improve hf, the largest us outpatient hf patient registry, has substantially contributed to our knowledge of how systolic hf and post mi left ventricular systolic dysfunction (lvsd) patients are treated in the outpatient setting. the findings of improve hf clearly support this guideline and may help to establish a model framework for future performance improvement programs for outpatient cardiology practices.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * primary or secondary diagnosis of heart failure or prior myocardial infarction (heart attack) * moderate-to-severe left ventricular dysfunction (lvd) as demonstrated by an ejection fraction \< or = 35% and/or a qualitative assessment of lvd of moderate-to-severe or severe lvd * patient has been seen at the clinic at least twice in the past 2 years * patient received care from the physician participating in the study exclusion criteria: * patient has died * patient is not expected to survive for 12 months due to medical conditions other than heart failure * patient has undergone heart transplant surgery

Keywords: systolic heart failure quality of care outcomes evidence-based guidelines recommended therapies
isotonic solutions and major adverse renal events trial in the non-medical intensive care unit (smart-surg)

Conditions: Critical Illness; Acute Kidney Injury

Summary: the administration of intravenous fluids is ubiquitous in the care of the critically ill. commonly available isotonic crystalloid solutions contain a broad spectrum electrolyte compositions including a range chloride concentrations. recent studies have associated solutions with supraphysiologic chloride content with hyperchloremia, metabolic acidosis and renal vasoconstriction, acute kidney injury and renal replacement therapy, and increased mortality but no large, randomized-controlled trials have been conducted. smart-surg will be a large, cluster-randomized, multiple-crossover trial enrolling critically ill patients from the non-medical icus at vanderbilt university from october 2015 until april 2017. the primary endpoint will be the incidence of major adverse kidney events in 30 days after enrollment (make30 is the composite of death, new renal replacement, or persistent renal dysfunction at discharge).

smart-surg is a large, cluster-randomized, multiple-crossover trial of 0.9% saline versus physiologically-balanced isotonic crystalloids (lactated ringers or plasma-lyte© a) with regard to the incidence of major adverse kidney events by 30 days in patients admitted to non-medical intensive care units. all patients admitted to participating non-medical intensive care units at vanderbilt university medical center who are 18 years or older will be enrolled. the study will occur in one-month blocks. each participating icu will be randomized to an initial fluid group (0.9% saline or physiologically balanced isotonic crystalloids). the assigned fluid will be used exclusively for all patients receiving isotonic crystalloid for the duration of the month-long block (except in the presence of pre-specified contraindications). the assigned study fluid will switch at the end of each month-long block such that half of the months are assigned to 0.9% saline and half of the months to physiologically balance fluid. the primary endpoint will be major adverse kidney events by 30 days (make30 is the composite of death, new renal replacement therapy, or persistent renal dysfunction at discharge). all aspects of study design, intervention, and data collection will be harmonized with an ongoing, independent study addressing the same question in the medical intensive care unit at vanderbilt university during a similar study period (smart-med). a pre-specified data analysis plan will dictate the harmonized analysis of smart-med and smart-surg.

Eligibility criteria:
inclusion criteria: * admitted to a participating non-medical intensive care unit (icu) at vanderbilt university medical center exclusion criteria: * age\<18 years old

Keywords: crystalloid acute kidney injury
caroverin and inner ear diseases

Conditions: Tinnitus

Summary: this trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom. the study will investigate the transtympanic treatment with a 1,5 % caroverine solution. each patient will undergo treatment for 2 cycles of 48 hours each.


Eligibility criteria:
inclusion criteria: * men or women aged at least eighteen * written consent to take part in the study after receiving information from the trial physician * one of the following illnesses: * decompensated tinnitus * sudden hearing loss * morbus menière * blast injury * presbyacusis with tinnitus * chron. otitis media exclusion criteria: * patients who are not able to give their consent (e.g. dementia, coma, mental disability,...) * women of childbearing age who are not using adequate contraception or who are (or plan to become) pregnant (a pregnancy test must be carried out by a doctor once a month in austria) or are lactating * if there are solid reasons to doubt that the patient would be willing and able to cooperate * known intolerance of/hypersensitivity to caroverine * subjects who have taken part in another clinical trial within the 30 days preceding the start of this study or during this study * pulse-synchronous tinnitus * tinnitus caused by malposition of the jaw bone (bruxism) * eardrum perforation * subjects who have previously had a barotraumas, diving accidents or decompression sickness * retrocochlear hearing disorder * patients who have previously had a fracture of the petrous bone * subjects suffering from acute or chronic accompanying conditions which severely impede their general health (nyha stage iv, cancer, hiv etc.) * accompanying conditions that according to the current state of scientific knowledge could affect the parameters used in this study to such an extent as to make it impossible to perform an objective assessment of those parameters, particularly ear conditions, including any conditions affecting the other ear or conditions like hi nyha stage iv, cancer, hiv, wallenberg syndrome, massive hypotension, glaucoma.) * accompanying medication that according to the current state of scientific knowledge are likely to affect the measurement techniques used in this study or the results obtained (cytostatics, aminoglycoside antibiotics, loop diuretics (furosemide, etacrynic acid), psycho pharmaceuticals, muscle relaxants, benzodiazepines, salicylates, quinine, cortisone and/or caroverine within the three days preceding the start of the study) * drug treatment for tinnitus or sudden hearing loss (i.v. and oral) within seven days preceding the start of the study where the total duration of the course is less than four weeks * diseases or conditions that may be associated with an altered perception or processing of stimuli, e.g. mental illness

Keywords: morbus meniere sudden hearing loss blast injury presbyacusis chron. otitis media